The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL) 2024 care pathway
Study Type
OBSERVATIONAL
Enrollment
1,233,970
No treatment given
Novo Nordisk Investigational Site
Bangalore, India
The proportion of people with low/intermediate/high risk of advanced fibrosis in EASL at risk population based on EASL 2024 care pathway.
Number and proportion of people in respective risk population
Time frame: January 1st, 2023, to December 31st, 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.